Clinical trial on termination of early pregnancy with RU486 in combination with prostaglandin
1992; Elsevier BV; Volume: 46; Issue: 3 Linguagem: Inglês
10.1016/0010-7824(92)90001-a
ISSN1879-0518
AutoresWu Shangchun, Gao Ji, Yuming Wu, Wu Muzh-En, Fan Huimin, Yao Guang-Zhen, Shurong Zheng, Wang Ping, Du Mingkun, Zirong Huang, Huang Ju-xiang, Zhu Ge, Zhen-wu Lei, Xiaoqin Chen, Peng Dun-Ren, Lijuan Song, Xirui Wu, Huang Sha, Xia Jingzhong, Zhang Jian-guo,
Tópico(s)Cardiac, Anesthesia and Surgical Outcomes
ResumoTermination of early pregnancy was performed in 1572 healthy women with RU486 (mifepristone, 600mg orally once), followed 36–60 hours later by administration of methyl ester of dl-15-methyl-PGF2α (PG05, 1mg vaginal suppository). Complete abortion was accomplished in 91.2% (), incomplete abortion in 4.8% (), and continued pregnancy in 3.9% (). The time elapsed between RU486 intake and complete expulsion was 2.4 ± 1.3 days. Expulsion took place on the third day in 935 women (72%), and on the 4th day in 273 women (21.0%). Uterine bleeding occurred on the second or third day after RU486 intake in 1256 women (88.8%), and lasted 11.7 ± 6.4 (SD) days, range 2–55 days. One subject had blood transfusion due to excessive bleeding. The main side effects were nausea/vomiting (22.3%), abdominal pain (10.2%), headache/dizziness (4.1%) and diarrhea (2.8%). Fatal side effects have not been reported in this study. About 73% of subjects with complete abortion assessed the treatment as good to excellent. Even in the failed cases, 25–42% of subjects considered the treatment as good. Further studies are needed to determine the optimal dose of the RU486 regimen. It should be emphasized that the treatment must be used under close medical supervision in order to monitor the uterine bleeding.
Referência(s)